Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation
US-11517879-B2 · Dec 6, 2022 · US
US12337293B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12337293-B2 |
| Application number | US-202217981262-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 4, 2022 |
| Priority date | Sep 29, 2006 |
| Publication date | Jun 24, 2025 |
| Grant date | Jun 24, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
Opening claim text (preview).
What is claimed is: 1. A chromatography ligand, which ligand comprises one or more Domain C units from Staphylococcus protein A (SpA), wherein the Domain C sequence has a sequence that is at least 94% identical to an amino acid sequence, the amino acid sequence being a sequence shown in SEQ ID NO:2 with mutation G25A. 2. The chromatography ligand according to claim 1 , wherein after 15 hours incubation in 0.5 M NaOH the ligand retains at least 80% of its binding capacity compared to the untreated ligand. 3. The chromatography ligand according to claim 1 , wherein after 15 hours incubation in 0.5 M NaOH the ligand retains at least 90% of its binding capacity compared to the untreated ligand. 4. The chromatography ligand according to claim 1 , wherein at least one asparagine in the sequence of the ligand is replaced with an amino acid other than glutamine or aspartic acid. 5. The chromatography ligand according to claim 1 , wherein the ligand is multimeric and comprises at least two Domain C mutants. 6. The chromatography ligand according to claim 1 , wherein the multimeric ligand comprises 2-8 Domain C units, optionally coupled via linker segments. 7. The chromatography ligand according to claim 1 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s). 8. The chromatography ligand according to claim 7 , wherein the terminal group comprises arginine or cysteine. 9. A separation matrix comprising the ligand of claim 1 . 10. The separation matrix according to claim 9 , wherein after 15 hours incubation in 0.5 M NaOH the ligand retains at least 80% of its binding capacity compared to the untreated ligand. 11. The separation matrix according to claim 9 , wherein after 15 hours incubation in 0.5 M NaOH the ligand retains at least 90% of its binding capacity compared to the untreated ligand. 12. The separation matrix according to claim 9 , wherein at least one asparagine in the sequence of the ligand is replaced with an amino acid other than glutamine or aspartic acid. 13. The separation matrix according to claim 9 , wherein the ligand is multimeric and comprises at least two Domain C mutants. 14. The separation matrix according to claim 9 , wherein the multimeric ligand comprises 2-8 Domain C units, optionally coupled via linker segments. 15. The separation matrix according to claim 9 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s). 16. The separation matrix according to claim 15 , wherein the terminal group comprises arginine or cysteine.
the carrier being a carbohydrate · CPC title
Sorbents specially adapted for analytical or investigative chromatography · CPC title
Sorbents specially adapted for preparative chromatography · CPC title
Coatings on a core, the core being particle or fiber shaped, e.g. encapsulated particles, coated fibers · CPC title
involving a particular spacer or linking group, e.g. for attaching an active group · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.